Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice.
Helicobacter pylori infection of the gastric mucosa is a significant cause of morbidity and mortality because of its etiologic role in symptomatic gastritis, peptic ulcer disease, and gastric adenocarcinoma. Infection occurs in young children; therefore, a prophylactic vaccine would have to be administered within the first year of life, a period thought to be immunologically privileged. We investigated vaccine formulations administered by different routes to confer protective anti-H. pylori immunity in neonatal mice. Neonatal mice immunized with a single dose of vaccine in complete Freund's adjuvant (CFA) generated antigen-specific gamma interferon-, interleukin-2 (IL-2)-, IL-4-, and IL-5-secreting T cells in numbers similar to those in immunized adult mice, while vaccine administered to neonates in incomplete Freund's adjuvant (IFA) induced such cells in reduced numbers compared to those in adult mice. Both IFA and CFA, however, provided partial protection from a challenge with infectious H. pylori when the vaccine was administered subcutaneously. Neonatal immunized mice also had reduced bacterial loads when immunized intraperitoneally with CFA. In all cases, protection was equivalent to that achieved when adult counterparts were immunized. These studies suggest that an efficacious vaccine might be successfully administered to very young children to prevent perinatal infection of H. pylori.
Eisenberg
Julia C
JC
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Czinn
Steven J
SJ
Garhart
Christine A
CA
Redline
Raymond W
RW
Bartholomae
Wolf C
WC
Gottwein
Judith M
JM
Nedrud
John G
JG
Emancipator
Steven E
SE
Boehm
Bernhard B
BB
Lehmann
Paul V
PV
Blanchard
Thomas G
TG
D000536:Aluminum Hydroxide / Q000276:immunology; D000818:Animals; D000831:Animals, Newborn; D000942:Antigens, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis; D005620:Freund's Adjuvant / Q000276:immunology*; D016481:Helicobacter Infections / Q000276:immunology / Q000517:prevention & control*; D016480:Helicobacter pylori / Q000276:immunology*; D007114:Immunization; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D016207:Cytokines; D000536:Aluminum Hydroxide; D005620:Freund's Adjuvant